MorphoSys Entered into a License Agreements with HIBio to Develop and Commercialize Felzartamab and MOR21 for Autoimmune and Inflammatory Diseases
Shots:
- MorphoSys to receive $15M up front for MOR210, 15% equity stake in HIBio along with equity earn-in provisions & standard investment rights, $1B upon achievement of development, regulatory & commercial milestones along with royalties on net sales of felzartamab & MOR210
- HIBio to get exclusive rights to develop & commercialize both products across all indications globally (Ex- Greater China for felzartamab & Greater China and South Korea for MOR210) & will lead the development & commercialization expenses
- The agreements allow MorphoSys to focus its resources to develop late & mid-stage oncology pipelines. Both companies combine their scientific expertise to advance both products into new therapies for patients
Ref: Bussinesswire | Image: MorphoSys
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
